Skip to main content

Kiniksa Pharmaceuticals International, plc

corporate_fare Company Profile

Kiniksa Pharmaceuticals International, plc

KNSA·NASDAQ·Life Sciences·CIK 0001730430

Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company that develops and commercializes new therapies for diseases with unmet medical needs, primarily focusing on cardiovascular conditions. The company's main product is ARCALYST, an interleukin-1α ("IL-1α") and interleukin-1β ("IL-1β") cytokine trap. Kiniksa licensed ARCALYST from Regeneron in 2017, acquiring exclusive worldwide rights, excluding the Middle East and North Africa, for all applications except oncology and local administration to the eye or ear. In March 2021, the FDA approved ARCALYST for treating recurrent pericarditis and reducing the risk of recurrence in adults and children aged 12 years and older. Recurrent pericarditis is an inflammatory cardiovascular disease affecting an estimated 40,000 patients in the United States who seek and receive medical treatment. ARCALYST is also approved in the United States for treating Cryopyrin-Associated Periodic Syndromes ("CAPS"), including Familial Cold Autoinflammatory Syndrome ("FCAS") and Muckle-Wells Syndrome in adults and children aged 12 years and older. Additionally, it is approved for maintaining remission in Deficiency of Interleukin-1 Receptor Antagonist ("DIRA") in adults and children weighing 10 kg or more. ARCALYST is sold across the United States through a network of specialty pharmacies. Kiniksa handles sales and distribution for all approved indications in the United States and shares profits from sales and third-party proceeds equally with Regeneron. In 2022, Kiniksa granted Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. ("Huadong") exclusive rights to develop and commercialize ARCALYST in the Huadong Territory. Regeneron began transferring the ARCALYST drug substance manufacturing process in 2023, and Kiniksa is working to qualify Samsung as its new contract development and manufacturing organization (CDMO). In December 2024, Kiniksa started a collaborative study with The Mayo Clinic (and Johns Hopkins University) to research ARCALYST's effects in treating cardiac sarcoidosis.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for KNSA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-30, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for KNSA spans 144, 10-Q, 8-K, 4.

Recent high-impact activity:

  • Kiniksa CEO/Chairman Patel Notices $51.6M Sale, Largest of Four Officer 144s
  • Kiniksa 10-Q: Q3 Revenue Up 58% to $286.0M, Net Income $47.3M, $568.8M Cash
  • Arcalyst Guidance Raised to $1.05B as Q3 Revenue Beats by $25M; Shares Jump 20%
  • Kiniksa Posts Q3 EPS of 56 Cents
  • Kiniksa Q2 ARCALYST Revenue Surges 55% to $243.6M; Full-Year Guidance Raised to $980–$995M

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$677.56M
Net Income
$59.01M
Diluted EPS
$0.75
Op. Cash Flow
$137.99M
Free Cash Flow
$136.42M
Gross Profit
$599.89M
Operating Income
$77.22M
Cash & Equivalents
$165.6M
Debt / Equity
0.00×
Net Margin
8.7%
Shares Outstanding
74.2M sh
Source: 10-K · filed 2026-02-24 · accession 0001104659-26-019168

Short Interest & Short Volume

3.89 days to cover

FINRA reported short interest of 4,294,644 shares in KNSA as of the October 30, 2026 settlement, a 14.1% increase from the prior period — about 3.9 days to cover at its recent average daily volume. On November 20, 2026, 58.7% of KNSA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)4,294,644 shares as of October 30, 2026
Change vs prior period▲ 14.1%
Days to cover3.89 at avg daily volume of 1,103,402
Daily short volume (FINRA facilities)58.7% of 207,515 shares on November 20, 2026
5-day average short volume51.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with K →
$95 +1.18% today
52-week range · as of 2026-10-30 $36.56 – $98.48
Market cap
$7.38B
Volume
545.2K (0.7× avg)
3-mo avg 827.2K
Live data · 2026-11-22 06:25 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed KNSA - Latest Insights

KNSA
Oct 30, 2026, 6:20 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $92.15
Real-time Price: $95.00 info
Change: +$2.85 (+3%) info
Market Cap: $7.377B info
KNSA
Oct 27, 2026, 4:36 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $89.40
Real-time Price: $95.00 info
Change: +$5.60 (+6%) info
Market Cap: $7.377B info
KNSA
Oct 27, 2026, 11:43 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $87.37
Real-time Price: $95.00 info
Change: +$7.63 (+9%) info
Market Cap: $7.377B info
KNSA
Oct 27, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $74.99
Real-time Price: $95.00 info
Change: +$20.01 (+27%) info
Market Cap: $7.377B info
KNSA
Jul 28, 2026, 4:17 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $79.95
Real-time Price: $95.00 info
Change: +$15.05 (+19%) info
Market Cap: $7.377B info
KNSA
Jul 28, 2026, 7:33 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $63.30
Real-time Price: $95.00 info
Change: +$31.70 (+50%) info
Market Cap: $7.377B info
KNSA
Jul 28, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $63.30
Real-time Price: $95.00 info
Change: +$31.70 (+50%) info
Market Cap: $7.377B info
KNSA
Jun 02, 2026, 4:50 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $46.70
Real-time Price: $95.00 info
Change: +$48.30 (+103%) info
Market Cap: $7.377B info
KNSA
May 26, 2026, 5:04 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $52.86
Real-time Price: $95.00 info
Change: +$42.14 (+80%) info
Market Cap: $7.377B info
KNSA
May 26, 2026, 4:55 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $52.86
Real-time Price: $95.00 info
Change: +$42.14 (+80%) info
Market Cap: $7.377B info
KNSA
Apr 28, 2026, 4:16 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $54.44
Real-time Price: $95.00 info
Change: +$40.56 (+75%) info
Market Cap: $7.377B info
KNSA
Apr 28, 2026, 7:32 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $46.00
Real-time Price: $95.00 info
Change: +$49.00 (+107%) info
Market Cap: $7.377B info
KNSA
Apr 28, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $46.50
Real-time Price: $95.00 info
Change: +$48.50 (+104%) info
Market Cap: $7.377B info
KNSA
Apr 16, 2026, 4:32 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $45.32
Real-time Price: $95.00 info
Change: +$49.68 (+110%) info
Market Cap: $7.377B info
KNSA
Feb 24, 2026, 4:39 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $42.70
Real-time Price: $95.00 info
Change: +$52.30 (+122%) info
Market Cap: $7.377B info
KNSA
Feb 24, 2026, 7:35 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $45.50
Real-time Price: $95.00 info
Change: +$49.50 (+109%) info
Market Cap: $7.377B info
KNSA
Jan 14, 2026, 4:31 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $39.56
Real-time Price: $95.00 info
Change: +$55.44 (+140%) info
Market Cap: $7.377B info
KNSA
Jan 12, 2026, 5:22 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $41.12
Real-time Price: $95.00 info
Change: +$53.88 (+131%) info
Market Cap: $7.377B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets